ArticlePsoriasis (Auckland, N.Z.)2026
Four Weeks of Biologic Treatment are Sufficient to Normalize Blunted HPA-Axis Activity and Significantly Improve Psychological Burden in Patients with Psoriasis.
Article in Psoriasis (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Psoriasis is associated with substantial psychological burden and dysregulation of endocrine pathways, including the hypothalamic-pituitary-adrenal (HPA) axis. Although biologic therapies improve skin disease, early changes in psychological burden and HPA-axis activity remain insufficiently characterized. This study addresses this scientific gap. Patients and Methods: This prospective observational study analyzed data from n = 50 patients with moderate-to-severe psoriasis who were assessed at baseline and after 4 weeks of biologic therapy, and from n = 50 matched healthy controls evaluated at baseline. Primary psychological outcomes were depressive symptoms, anxiety, and perceived stress, measured using Beck's Depression Inventory (BDI), the State-Trait Anxiety-Depression Inventory (STADI), and the Perceived Stress Scale (PSS). Plasma cortisol levels were analyzed in a sampling-time-matched subgroup of n = 25 patients and n = 25 healthy controls. Results: At baseline, patients with psoriasis showed pronounced psychological distress compared with healthy controls, including higher depressive symptoms, state and trait anxiety, state and trait depression, and perceived stress. After 4 weeks of biologic treatment, patients with psoriasis showed significant improvements in BDI, STADI state anxiety, STADI trait anxiety, and PSS scores (all p ≤0.002). By week 4, BDI scores, trait anxiety, and perceived stress were no longer different between patients and controls according to Bonferroni-adjusted tests. Baseline plasma cortisol in patients with psoriasis was lower than in controls (p =0.015) and increased significantly after 4 weeks (p =0.008), no longer differing from healthy controls (p =0.839). Concurrently, PASI decreased from 16.9 to 7.2 after 4 weeks of biologic therapy (p <0.001). Conclusion: After only 4 weeks of biologic therapy, patients with psoriasis showed marked improvement in psychological burden, and plasma cortisol shifted from a reduced baseline level toward the range observed in healthy controls, consistent with early normalization of HPA-axis activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.